[1]
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 2021; 71: 7-33.
[2]
Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin 2020; 70: 145-64.
[3]
Islami F, Goding Sauer A, Miller KD, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin 2018; 68: 31-54.
[4]
Lortet‐Tieulent J, Georges D, Bray F, Vaccarella S. Profiling global cancer incidence and mortality by socioeconomic development. Int J Cancer 2020; 147: 3029-36.
[5]
Marjaneh RM, Khazaei M, Ferns GA, Avan A, Aghaee-Bakhtiari SH. The role of microRNAs in 5-FU resistance of colorectal cancer: Possible mechanisms. J Cell Physiol 2019; 234: 2306-16.
[6]
Modest D, Pant S, Sartore-Bianchi A. Treatment sequencing in metastatic colorectal cancer. Eur J Cancer 2019; 109: 70-83.
[7]
Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-90.
[8]
Lim J, Thiery JP. Epithelial-mesenchymal transitions: Insights from development. Development 2012; 139: 3471-86.
[9]
Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol 2019; 20: 69-84.
[10]
Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: The mechanistic link and clinical implications. Nat Rev Clin Oncol 2017; 14: 611-29.
[11]
Nieto MA. Epithelial plasticity: A common theme in embryonic and cancer cells. Science 2013; 342(6159): 1234850.
[12]
Ocaña OH, Córcoles R, Fabra Á, et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 2012; 22: 709-24.
[13]
Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012; 22: 725-36.
[14]
Gupta S, Mathur M, Miao B, Suravajhala P, Bandapalli OR. Role
of DNA mismatch repair genes in colorectal cancer. In: Colon
Cancer Diagnosis and Therapy. Springer Cham 2021. 2: pp. 209-
23.
[15]
Bai H, Wang R, Cheng W, et al. Evaluation of concordance between deficient mismatch repair and microsatellite instability testing and their association with clinicopathological features in colorectal cancer. Cancer Manag Res 2020; 12: 2863.
[16]
Aghabozorgi AS, Bahreyni A, Soleimani A, et al. Role of Adenomatous Polyposis Coli (APC) gene mutations in the pathogenesis of colorectal cancer; current status and perspectives. Biochimie 2019; 157: 64-71.
[17]
Joung JG, Oh BY, Hong HK, et al. Tumor heterogeneity predicts metastatic potential in colorectal cancer. Clin Cancer Res 2017; 23: 7209-16.
[18]
Giovannetti E, Wang Q, Avan A, et al. Role of CYB5A in pancreatic cancer prognosis and autophagy modulation. J Natl Cancer Inst 2014; 106: djt346.
[19]
Yun JA, Kim SH, Hong HK, et al. Loss of E-cadherin expression is associated with a poor prognosis in stage III colorectal cancer. Oncology 2014; 86: 318-28.
[20]
Yan X, Yan L, Liu S, et al. N-cadherin, a novel prognostic biomarker, drives malignant progression of colorectal cancer. Mol Med Rep 2015; 12: 2999-3006.
[21]
Shioiri M, Shida T, Koda K, et al. Slug expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Br J Cancer 2006; 94: 1816-22.
[22]
Côme C, Magnino F, Bibeau F, et al. Snail and slug play distinct roles during breast carcinoma progression. Clin Cancer Res 2006; 12: 5395-402.
[23]
Toiyama Y, Yasuda H, Saigusa S, et al. Increased expression of slug and vimentin as novel predictive biomarkers for lymph node metastasis and poor prognosis in colorectal cancer. Carcinogenesis 2013; 34: 2548-57.
[24]
Zhang GJ, Zhou T, Tian HP, Liu ZL, Xia SS. High expression of ZEB1 correlates with liver metastasis and poor prognosis in colorectal cancer. Oncol Lett 2013; 5: 564-8.
[25]
Kahlert C, Lahes S, Radhakrishnan P, et al. Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro. Clin Cancer Res 2011; 17: 7654-63.
[26]
Yi W, Xiao E, Ding R, Luo P, Yang Y. High expression of fibronectin is associated with poor prognosis, cell proliferation and malignancy via the NF-κB/p53-apoptosis signaling pathway in colorectal cancer. Oncol Rep 2016; 36: 3145-53.
[27]
Gomez I, Peña C, Herrera M, et al. TWIST1 is expressed in colorectal carcinomas and predicts patient survival. PLoS One 2011; 6: e18023.
[28]
Bahrami A, Hassanian SM, Khazaei M, et al. The therapeutic potential of targeting tumor microenvironment in breast cancer: Rational strategies and recent progress. J Cell Biochem 2018; 119: 111-22.
[29]
Fedele M, Sgarra R, Battista S, Cerchia L, Manfioletti G. The epithelial-mesenchymal transition at the crossroads between metabolism and tumor progression. Int J Mol Sci 2022; 23(2): 800.
[30]
Maftouh M, Belo AI, Avan A, et al. Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/β-catenin signalling in pancreatic adenocarcinoma. Oncotarget 2014; 5: 5335-49.
[31]
Pohl M, Radacz Y, Pawlik N, et al. SMAD4 mediates mesenchymal-epithelial reversion in SW480 colon carcinoma cells. Anticancer Res 2010; 30: 2603-13.
[32]
Amerizadeh F, Rezaei N, Rahmani F, et al. Crocin synergistically enhances the antiproliferative activity of 5-flurouracil through Wnt/PI3K pathway in a mouse model of colitis-associated colorectal cancer. J Cell Biochem 2018; 119: 10250-61.
[33]
Wu ZQ, Li XY, Hu CY, et al. Canonical Wnt signaling regulates slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression. Proc Natl Acad Sci 2012; 109: 16654-9.
[34]
Vu T, Datta PK. Regulation of EMT in colorectal cancer: A culprit in metastasis. Cancers 2017; 9(12): 171.
[35]
Sierra JR, Tsao MS. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol 2011; 3: S21-35.
[36]
Du L, Li J, Lei L, et al. High vimentin expression predicts a poor prognosis and progression in colorectal cancer: A study with meta-analysis and tcga database. BioMed Res Int 2018; 2018: 6387810.
[37]
Roseweir AK, Kong CY, Park JH, et al. A novel tumor-based epithelial-to-mesenchymal transition score that associates with prognosis and metastasis in patients with Stage II/III colorectal cancer. Int J Cancer 2019; 144: 150-9.
[38]
Kwon CH, Park HJ, Choi JH, et al. Snail and serpinA1 promote tumor progression and predict prognosis in colorectal cancer. Oncotarget 2015; 6: 20312-26.
[39]
Kopalli SR, Cha K-M, Ryu JH, Hwang SY, Kim SK. Specific activity of Korean red ginseng saponin and non-saponin fractions in ageing-induced rat testicular dysfunction. J Funct Foods 2017; 29: 226-37.
[40]
Oh HA, Kim DE, Choi HJ, Kim NJ, Kim DH. Anti-stress effects of 20 (S)-protopanaxadiol and 20 (S)-protopanaxatriol in immobilized mice. Biol Pharm Bull 2015; 38: 331-5.
[41]
Li X, Liu W, Geng C, et al. Ginsenoside Rg3 suppresses epithelial-mesenchymal transition via downregulating notch-hes1 signaling in colon cancer cells. Am J Chin Med 2021; 49: 217-35.
[42]
Dai G, Sun B, Gong T, et al. Ginsenoside Rb2 inhibits epithelial-mesenchymal transition of colorectal cancer cells by suppressing TGF-β/Smad signaling. Phytomedicine 2019; 56: 126-35.
[43]
Phi LTH, Wijaya YT, Sari IN, et al. The anti-metastatic effect of ginsenoside Rb2 in colorectal cancer in an EGFR/SOX2-dependent manner. Cancer Med 2018; 7: 5621-31.
[44]
Zhang E, Shi H, Yang L, Wu X, Wang Z. Ginsenoside Rd regulates the Akt/mTOR/p70S6K signaling cascade and suppresses angiogenesis and breast tumor growth. Oncol Rep 2017; 38: 359-67.
[45]
Lee SY, Kim GT, Roh SH, et al. Proteome changes related to the anti-cancer activity of HT29 cells by the treatment of ginsenoside Rd. Pharmazie 2009; 64: 242-7.
[46]
Kim YJ, Yamabe N, Choi P, et al. Efficient thermal deglycosylation of ginsenoside Rd and its contribution to the improved anticancer activity of ginseng. J Agric Food Chem 2013; 61: 9185-91.
[47]
Phi LTH, Sari IN, Wijaya YT, et al. Ginsenoside Rd inhibits the metastasis of colorectal cancer via epidermal growth factor receptor signaling axis. IUBMB Life 2019; 71: 601-10.
[48]
Adams DJ, Dai M, Pellegrino G, et al. Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs. Proc Natl Acad Sci 2012; 109: 15115-20.
[49]
Thongsom S, Suginta W, Lee KJ, Choe H, Talabnin C. Piperlongumine induces G2/M phase arrest and apoptosis in cholangiocarcinoma cells through the ROS-JNK-ERK signaling pathway. Apoptosis 2017; 22: 1473-84.
[50]
Moradi-Marjaneh R, Hassanian SM, Fiuji H, et al. Toll like receptor signaling pathway as a potential therapeutic target in colorectal cancer. J Cell Physiol 2018; 233: 5613-22.
[51]
Kumar S, Agnihotri N. Piperlongumine targets NF-κB and its downstream signaling pathways to suppress tumor growth and metastatic potential in experimental colon cancer. Mol Cell Biochem 2021; 476: 1765-81.
[52]
Hu J, Yang Z, Wu H, Wang D. Rhein attenuates renal inflammatory injury of uric acid nephropathy via lincRNA-Cox2/miR-150-5p/STAT1 axis. Int Immunopharmacol 2020; 85: 106620.
[53]
Zhang H, Yi JK, Huang H, et al. Rhein suppresses colorectal cancer cell growth by inhibiting the mtor pathway in vitro and in vivo. Cancers 2021; 13: 2176.
[54]
Katoch A, Nayak D, Faheem MM, et al. Natural podophyllotoxin analog 4DPG attenuates EMT and colorectal cancer progression via activation of checkpoint kinase 2. Cell Death Discov 2021; 7: 25.
[55]
Jiang F, Ren S, Chen Y, et al. Fangchinoline exerts antitumour activity by suppressing the EGFR-PI3K/AKT signalling pathway in colon adenocarcinoma. Oncol Rep 2021; 45: 139-50.
[56]
Ji Q, Liu X, Han Z, et al. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated snail/E-cadherin expression. BMC Cancer 2015; 15: 1-12.
[57]
Yuan L, Zhou M, Huang D, et al. Resveratrol inhibits the invasion and metastasis of colon cancer through reversal of epithelial-mesenchymal transition via the AKT/GSK-3β/snail signaling pathway. Mol Med Rep 2019; 20: 2783-95.
[58]
Gu M, Lu L, Wei Q, et al. Improved oral bioavailability and anti-chronic renal failure activity of chrysophanol via mixed polymeric micelles. J Microencapsul 2021; 38: 47-60.
[59]
Wen Q, Mei L, Ye S, et al. Chrysophanol demonstrates anti-inflammatory properties in LPS-primed RAW 264.7 macrophages through activating PPAR-γ. Int Immunopharmacol 2018; 56: 90-7.
[60]
Deng M, Xue YJ, Xu LR, et al. Chrysophanol suppresses hypoxia-induced epithelial-mesenchymal transition in colorectal cancer cells. Anat Rec 2019; 302: 1561-70.
[61]
Li DD, Zhao CH, Ding HW, et al. A novel inhibitor of ADAM 17 sensitizes colorectal cancer cells to 5‐fluorouracil by reversing notch and epithelial‐mesenchymal transition in vitro and in vivo. Cell Prolif 2018; 51: e12480.
[62]
Spiegelberg D, Mortensen ACL, Palupi KD, et al. The novel anti-cMet antibody seeMet 12 potentiates sorafenib therapy and radiotherapy in a colorectal cancer model. Front Oncol 2020; 10: 1717.
[63]
Xiao J, Zhou N, Li Y, et al. PEITC inhibits the invasion and migration of colorectal cancer cells by blocking TGF-β-induced EMT. Biomed Pharmacother 2020; 130: 110743.
[64]
Buhrmann C, Brockmueller A, Harsha C, et al. Evidence that tumor microenvironment initiates epithelial-to-mesenchymal transition and calebin a can suppress it in colorectal cancer cells. Front Pharmacol 2021; 12: 1689.
[65]
Chen P, Li X, Zhang R, et al. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation. Theranostics 2020; 10: 5107-19.
[66]
Jia YT, Yang DH, Zhao Z, et al. Effects of PHA-665752 and cetuximab combination treatment on in vitro and murine xenograft growth of human colorectal cancer cells with KRAS or BRAF mutations. Curr Cancer Drug Targets 2018; 18: 278-86.
[67]
Kirane A, Toombs JE, Larsen JE, et al. Epithelial–mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib. Carcinogenesis 2012; 33: 1639-46.
[68]
Dovizio M, Maier TJ, Alberti S, et al. Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells. Mol Pharmacol 2013; 84: 25-40.
[69]
Shen T, Cheng X, Xia C, et al. Erlotinib inhibits colon cancer metastasis through inactivation of TrkB‐dependent ERK signaling pathway. J Cell Biochem 2019; 120: 11248-55.
[70]
Li Y, Wang LH, Zhang HT, et al. Disulfiram combined with copper inhibits metastasis and epithelial–mesenchymal transition in hepatocellular carcinoma through the NF‐κB and TGF‐β pathways. J Cell Mol Med 2018; 22: 439-51.
[71]
Han D, Wu G, Chang C, et al. Disulfiram inhibits TGF-β-induced epithelial-mesenchymal transition and stem-like features in breast cancer via ERK/NF-κB/Snail pathway. Oncotarget 2015; 6: 40907.
[72]
Liu Z, Mi M, Zheng X, et al. miR-30a/SOX4 double negative feedback loop is modulated by disulfiram and regulates EMT and stem cell-like properties in breast cancer. J Cancer 2021; 12: 5053-65.
[73]
Liu L, Zhang Z, Zhang G, et al. Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib. J Transl Med 2020; 18: 1-19.
[74]
Schacke M, Kumar J, Colwell N, et al. PARP-1/2 inhibitor olaparib prevents or partially reverts EMT induced by TGF-β in NMuMG cells. Int J Mol Sci 2019; 20: 518.
[75]
Wang H, Zhang H, Sun Z, Chen W, Miao C. GABAB receptor inhibits tumor progression and epithelial-mesenchymal transition via the regulation of Hippo/YAP1 pathway in colorectal cancer. Int J Biol Sci 2021; 17: 1953.
[76]
Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 2006; 12: 3657-60.
[77]
Armstrong GR, Khot MI, Tiernan JP, et al. The utility of c‐Met as a diagnostic tissue biomarker in primary colorectal cancer. Int J Exp Pathol 2021; 102: 172-8.
[78]
Parizadeh SM, Jafarzadeh‐Esfehani R, Fazilat‐Panah D, et al. The potential therapeutic and prognostic impacts of the c‐MET/HGF signaling pathway in colorectal cancer. IUBMB Life 2019; 71: 802-11.
[79]
Yao HP, Tong XM, Hudson R, Wang MH. MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: Molecular features as drug targets and antibody-drug conjugates for therapy. J Exp Clin Cancer Res 2020; 39: 1-18.
[80]
Bahrami A, Shahidsales S, Khazaei M, et al. C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives. J Cell Physiol 2017; 232: 2657-73.
[81]
Bardelli A, Corso S, Bertotti A, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013; 3: 658-73.
[82]
Liska D, Chen CT, Bachleitner-Hofmann T, Christensen JG, Weiser MR. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res 2011; 17: 472-82.
[83]
Troiani T, Martinelli E, Napolitano S, et al. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. Clin Cancer Res 2013; 19: 6751-65.
[84]
Rovithi M, Avan A, Funel N, et al. Development of bioluminescent Chick Chorioallantoic Membrane (CAM) models for primary pancreatic cancer cells: A platform for drug testing. Sci Rep 2017; 7: 44686.
[85]
He AR, Cohen RB, Denlinger CS, et al. First-in-human phase I study of merestinib, an oral multikinase inhibitor, in patients with advanced cancer. Oncologist 2019; 24: e930-42.
[86]
Saleh M, Cassier P, Eberst L, et al. Ramucirumab plus merestinib in previously treated metastatic colorectal cancer: Safety, pharmacokinetic, and preliminary efficacy findings from a Phase 1 study. Ann Oncol 2019; 30: iv124.
[87]
Yang JJ, Fang J, Shu YQ, et al. A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer. Invest New Drugs 2021; 39: 477-87.
[88]
Choueiri TK, Heng DY, Lee JL, et al. Efficacy of savolitinib vs sunitinib in patients with MET-driven papillary renal cell carcinoma: The SAVOIR phase 3 randomized clinical trial. JAMA Oncol 2020; 6: 1247-55.
[89]
Van Cutsem E, Eng C, Nowara E, et al. Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clin Cancer Res 2014; 20: 4240-50.
[90]
Eng C, Bessudo A, Hart LL, et al. A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy. Int J Cancer 2016; 139: 177-86.
[91]
Rimassa L, Bozzarelli S, Pietrantonio F, et al. Phase II study of tivantinib and cetuximab in patients with KRAS wild-type metastatic colorectal cancer with acquired resistance to EGFR inhibitors and emergence of met overexpression: Lesson learned for future trials with EGFR/met dual inhibition. Clin Colorectal Cancer 2019; 18: 125-132.e2.
[92]
Bendell JC, Hochster H, Hart LL, et al. A Phase II randomized trial (go27827) of first-line folfox plus bevacizumab with or without the met inhibitor onartuzumab in patients with metastatic colorectal cancer. Oncologist 2017; 22: 264-71.
[93]
Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal 2014; 7: re8.
[94]
Davis FM, Stewart TA, Thompson EW, Monteith GR. Targeting EMT in cancer: Opportunities for pharmacological intervention. Trends Pharmacol Sci 2014; 35: 479-88.
[95]
Nedaeinia R, Avan A, Manian M, Salehi R, Ghayour-Mobarhan M. EGFR as a potential target for the treatment of pancreatic cancer: Dilemma and controversies. Curr Drug Targets 2014; 15: 1293-301.
[96]
Ward KR, Zhang KX, Somasiri AM, Roskelley CD, Schrader JW. Expression of activated M-Ras in a murine mammary epithelial cell line induces epithelial-mesenchymal transition and tumorigenesis. Oncogene 2004; 23: 1187-96.
[97]
Park YL, Kim HP, Ock CY, et al. EMT-mediated regulation of CXCL1/5 for resistance to anti-EGFR therapy in colorectal cancer. Oncogene 2022; 41(14): 2026-38.
[98]
Zhou J, Ji Q, Li Q. Resistance to anti-EGFR therapies in metastatic colorectal cancer: Underlying mechanisms and reversal strategies. J Exp Clin Cancer Res 2021; 40: 328.
[99]
Santos EDS, Nogueira KAB, Fernandes LCC, et al. EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles. Int J Pharm 2021; 592: 120082.
[100]
Hartimath SV, El-Sayed A, Makhlouf A, et al. Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft. Oncotarget 2019; 10: 1031-44.
[101]
Elez E, Hendlisz A, Delaunoit T, et al. Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer. Br J Cancer 2016; 114: 372-80.
[102]
Van Emburgh BO, Arena S, Siravegna G, et al. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nat Commun 2016; 7: 13665.
[103]
Bertotti A, Papp E, Jones S, et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 2015; 526: 263-7.
[104]
Dienstmann R, Patnaik A, Garcia-Carbonero R, et al. Safety and activity of the first-in-class sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer. Cancer Discov 2015; 5: 598-609.
[105]
Sánchez-Martín FJ, Bellosillo B, Gelabert-Baldrich M, et al. The first-in-class anti-EGFR antibody mixture sym004 overcomes cetuximab resistance mediated by EGFR extracellular domain mutations in colorectal cancer. Clin Cancer Res 2016; 22: 3260-7.
[106]
Napolitano S, Martini G, Martinelli E, et al. Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation. Oncotarget 2017; 8: 67592-604.
[107]
Montagut C, Argilés G, Ciardiello F, et al. Efficacy of Sym004 in patients with metastatic colorectal cancer with acquired resistance to anti-EGFR therapy and molecularly selected by circulating tumor DNA analyses: A phase 2 randomized clinical trial. JAMA Oncol 2018; 4: e175245-5.
[108]
Yao C, Su L, Shan J, et al. IGF/STAT3/NANOG/Slug signaling axis simultaneously controls epithelial‐mesenchymal transition and stemness maintenance in colorectal cancer. Stem Cells 2016; 34: 820-31.
[109]
Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, et al. IGF-1R/Epithelial-to-Mesenchymal Transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations. Sci Rep 2013; 3: 1-15.
[110]
Bendell JC, Jones SF, Hart L, et al. A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer. Invest New Drugs 2015; 33: 187-93.
[111]
Cohn AL, Tabernero J, Maurel J, et al. A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. Ann Oncol 2013; 24: 1777-85.
[112]
Sclafani F, Kim TY, Cunningham D, et al. A randomized phase ii/iii study of dalotuzumab in combination with cetuximab and irinotecan in chemorefractory, KRAS wild-type, metastatic colorectal cancer. J Natl Cancer Inst 2015; 107: djv258.
[113]
Wilky BA, Rudek MA, Ahmed S, et al. A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours. Br J Cancer 2015; 112: 24-31.
[114]
Lin EH, Lenz HJ, Saleh MN, et al. A randomized, phase II study of the anti‐insulin‐like growth factor receptor type 1 (IGF‐1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer. Cancer Med 2014; 3: 988-97.
[115]
Becerra CR, Salazar R, Garcia-Carbonero R, et al. Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: A nonrandomized, open-label, phase II trial. Cancer Chemother Pharmacol 2014; 73: 695-702.
[116]
Strickler JH, Rushing CN, Uronis HE, et al. Cabozantinib and panitumumab for RAS wild-type metastatic colorectal cancer. Oncologist 2021; 26: 465-e917.
[117]
Bang YJ, Su WC, Schuler M, et al. Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts. Cancer Sci 2020; 111: 536-47.
[118]
Delord JP, Argilés G, Fayette J, et al. A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment. Invest New Drugs 2020; 38(6): 1774-83.
[119]
Massihnia D, Avan A, Funel N, et al. Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer. J Hematol Oncol 2017; 10: 9.
[120]
Maftouh M, Avan A, Funel N, et al. miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells. Nucleosides Nucleotides Nucleic Acids 2014; 33: 384-93.
[121]
Mésange P, Bouygues A, Ferrand N, et al. Combinations of bevacizumab and erlotinib show activity in colorectal cancer independent of RAS status. Clin Cancer Res 2018; 24: 2548-58.
[122]
Tournigand C, Chibaudel B, Samson B, et al. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): A randomised, open-label, phase 3 trial. Lancet Oncol 2015; 16: 1493-505.
[123]
Hagman H, Frödin JE, Berglund Å, et al. A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: The Nordic ACT2 trial. Ann Oncol 2016; 27: 140-7.
[124]
Karzai F, VanderWeele D, Madan RA, et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immunother Cancer 2018; 6: 141.
[125]
Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials. Lancet 2012; 379: 1591-601.
[126]
Yang L, Lv Z, Xia W, et al. The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: A phase II trial study. Clin Transl Oncol 2018; 20: 912-21.
[127]
Andre T, Tournigand C, Mineur L, et al. Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: A GERCOR study. Ann Oncol 2007; 18: 77-81.
[128]
Chen EY, Blanke CD, Haller DG, et al. A phase II study of celecoxib with irinotecan, 5-fluorouracil, and leucovorin in patients with previously untreated advanced or metastatic colorectal cancer. Am J Clin Oncol 2018; 41: 1193.
[129]
Haldar R, Ricon‐Becker I, Radin A, et al. Perioperative COX2 and β‐adrenergic blockade improves biomarkers of tumor metastasis, immunity, and inflammation in colorectal cancer: A randomized controlled trial. Cancer 2020; 126: 3991-4001.
[130]
Oh BS, Im E, Lee HJ, et al. Inhibition of TMPRSS4 mediated epithelial‐mesenchymal transition is critically involved in antimetastatic effect of melatonin in colorectal cancers. Phytother Res 2021; 35(8): 4538-46.
[131]
Zou Y, Zhao D, Yan C, et al. Novel ligustrazine-based analogs of piperlongumine potently suppress proliferation and metastasis of colorectal cancer cells in vitro and in vivo. J Med Chem 2018; 61: 1821-32.
[132]
Xiao W, Liu Y, Dai M, et al. Rotenone restrains colon cancer cell viability, motility and epithelial-mesenchymal transition and tumorigenesis in nude mice via the PI3K/AKT pathway. Int J Mol Med 2020; 46: 700-8.
[133]
Lu Z, Liu H, Fu W, et al. 20 (S)‐Protopanaxadiol inhibits epithelial‐mesenchymal transition by promoting retinoid X receptor alpha in human colorectal carcinoma cells. J Cell Mol Med 2020; 24: 14349-65.
[134]
Park JH. Effects of metformin and phenformin on apoptosis and epithelial‐mesenchymal transition in chemoresistant rectal cancer. Cancer Sci 2019; 110: 2834.
[135]
Zhang C, Wang Y. Metformin attenuates cells stemness and epithelial-mesenchymal transition in colorectal cancer cells by inhibiting the Wnt3a/β-catenin pathway. Mol Med Rep 2019; 19: 1203-9.
[136]
Chei S, Oh HJ, Song JH, et al. Magnolol suppresses TGF-β-induced epithelial-to-mesenchymal transition in human colorectal cancer cells. Front Oncol 2019; 9: 752.
[137]
Tong J, Shen Y, Zhang Z, et al. Apigenin inhibits epithelial-mesenchymal transition of human colon cancer cells through NF-κB/Snail signaling pathway. Biosci Rep 2019; 39.
[138]
Wang P, Gao XY, Yang SQ, et al. Jatrorrhizine inhibits colorectal carcinoma proliferation and metastasis through Wnt/β-catenin signaling pathway and epithelial–mesenchymal transition. Drug Des Devel Ther 2019; 13: 2235.
[139]
Yang Y, Zhang P, Yan R, et al. MnTE-2-PyP attenuates TGF-β-induced epithelial-mesenchymal transition of colorectal cancer cells by inhibiting the Smad2/3 signaling pathway. Oxidative medicine
and cellular longevity 2019; 2019: 8639791.
[140]
Zhu SM, Park YR, Seo SY, et al. Parthenolide inhibits transforming growth factor β1-induced epithelial-mesenchymal transition in colorectal cancer cells. Intest Res 2019; 17: 527-36.
[141]
Shi G, Zheng X, Wu X, et al. All‐trans retinoic acid reverses epithelial‐mesenchymal transition in paclitaxel‐resistant cells by inhibiting nuclear factor kappa B and upregulating gap junctions. Cancer Sci 2019; 110: 379-88.
[142]
Gu J, Cui CF, Yang L, Wang L, Jiang XH. Emodin inhibits colon cancer cell invasion and migration by suppressing epithelial-mesenchymal transition via the wnt/β-catenin pathway. Oncol Res 2019; 27: 193-202.
[143]
Zhang JW, Li LX, Wu WZ, et al. Anti-tumor effects of paeoniflorin on epithelial-to-mesenchymal transition in human colorectal cancer cells. Med Sci Monit 2018; 24: 6405-13.
[144]
Zhang Z, Xu J, Liu B, et al. Ponicidin inhibits pro-inflammatory cytokine TNF-α-induced epithelial–mesenchymal transition and metastasis of colorectal cancer cells via suppressing the AKT/] GSK-3β/Snail pathway. Inflammopharmacology 2019; 27: 627-38.
[145]
Dermani FK, Amini R, Saidijam M, et al. Zerumbone inhibits epithelial‐mesenchymal transition and cancer stem cells properties by inhibiting the β‐catenin pathway through miR‐200c. J Cell Physiol 2018; 233: 9538-47.
[146]
Feng J, Song D, Jiang S, et al. Quercetin restrains TGF-β1-induced epithelial–mesenchymal transition by inhibiting Twist1 and regulating E-cadherin expression. Biochem Biophys Res Commun 2018; 498: 132-8.
[147]
Sun D, Shen W, Zhang F, et al. α-Hederin inhibits interleukin 6-induced epithelial-to-mesenchymal transition associated with disruption of JAK2/STAT3 signaling in colon cancer cells. Biomed Pharmacother 2018; 101: 107-14.
[148]
Zhou P, Wang C, Hu Z, et al. Genistein induces apoptosis of colon cancer cells by reversal of epithelial-to-mesenchymal via a Notch1/NF-κB/slug/E-cadherin pathway. BMC Cancer 2017; 17: 1-10.
[149]
Liu Y, Lang T, Jin B, et al. Luteolin inhibits colorectal cancer cell epithelial-to-mesenchymal transition by suppressing CREB1 expression revealed by comparative proteomics study. J Proteomics 2017; 161: 1-10.
[150]
Ye Q, Su L, Chen D, Zheng W, Liu Y. Astragaloside IV induced miR-134 expression reduces EMT and increases chemotherapeutic sensitivity by suppressing CREB1 signaling in colorectal cancer cell line SW-480. Cell Physiol Biochem 2017; 43: 1617-26.
[151]
Zhao X, Han Z, Ma J, Jiang S, Li X. A Novel N-Sulfonylamidine-based derivative inhibits proliferation, migration, and invasion in human colorectal cancer cells by suppressing wnt/β-catenin signaling pathway. Pharmaceutics 2021; 13: 651.
[152]
Song Q, Yang L, Han Z, et al. Tanshinone IIA inhibits epithelial-to-mesenchymal transition through hindering β-arrestin1 mediated β-catenin signaling pathway in colorectal cancer. Front Pharmacol 2020; 11: 1712.
Download PDF Flyer